• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Will Smith & Nephew split up too?

Will Smith & Nephew split up too?

March 28, 2014 By Brad Perriello

Will Smith & Nephew split up too?

Smith & Nephew (FTSE:SN, NYSE:SNN) shares gained in London and New York today on an analyst’s speculation that the British medical device maker is ripe for a spinout akin to the Baxter (NYSE:BAX) split announced this week.

Nicholas Keher, an analyst with Investec, said Smith & Nephew could unlock value for shareholders by splitting its 3 main divisions – advanced wound management, endoscopy and orthopedics – into independent companies.

"Smith & Nephew is beginning to look like a growth stock again – we forecast a 3-year earnings per share compound annual growth rate over 10% and believe a re-rating is due," Keher wrote. "Moreover, we believe even more value could be created by breaking up the group into 3 separate entities."

The speculation pushed SN shares up 2.4% to £92.17 apiece as of the market’s close in London today. In New York, SNN shares rose 2.4% to $77.04 apiece as of about 1:10 p.m. today.

Keher said each of Smith & Nephew’s divisions is large enough to carry its own water.

"Moreover, we think each operates with such distinct business models that they require different strategies for capital allocation. We also struggle to identify adequate synergies in sales, manufacturing or R&D to justify the current combined structure. Recent examples illustrate the market’s appreciation for more streamlined business models with Abbott spinning out AbbVie and Covidien listing Mallinckrodt. Smith & Nephew’s chief executive also has past experience in deals of this sort," Keher wrote. "Whilst a break up has not been suggested or discussed by management, we feel the markets are ready and supportive. We believe there are key events that could act as potential triggers. These include the approval or positive Phase III data from HP802-247 (an AWM pipeline asset), the realization of synergy benefits from the Arthrocare acquisition or a large acquisition focused on orthopedics to drive growth rates within that division."

Earlier this week, Baxter announced its plan to spin out its pharmaceuticals business. In 2011, Abbott announced its plans for a similar split, saying it would carve out its pharma operation as a new, publicly traded company later named AbbVie (NYSE:ABBV). Later that year, Covidien said it would also divest its own pharmaceuticals division as Mallinckrodt plc (NYSE: MNK). And late last year, Kimberly-Clark (NYSE:KMB) shares hit a 52-week high on the news of its plan to spin out its medical device and health products division as a separate public company called K-C Health Care.

Filed Under: News Well, Wall Street Beat Tagged With: Smith & Nephew

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy